Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2012 | 1 |
2023 | 1 |
2024 | 2 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Significance of fusion status, Oberlin risk factors, local and maintenance treatment in pediatric and adolescent patients with metastatic rhabdomyosarcoma: Data of the European Soft Tissue Sarcoma Registry SoTiSaR.
Pediatr Blood Cancer. 2024 Jan;71(1):e30707. doi: 10.1002/pbc.30707. Epub 2023 Oct 9.
Pediatr Blood Cancer. 2024.
PMID: 37814424
BACKGROUND: Outcome of primary metastatic rhabdomyosarcoma (RMS) is poor. Certain risk factors as fusion status, Oberlin score, and local treatment of primary tumor are known to influence prognosis. ...RESULTS: In the European Soft Tissue Sarcoma Registry SoTiSaR (2009-201 …
BACKGROUND: Outcome of primary metastatic rhabdomyosarcoma (RMS) is poor. Certain risk factors as fusion status, Oberlin score, and l …
Treatment of nasolabial fold rhabdomyosarcoma in children: A single-institution experience.
Zhang G, Sun N, Ni X, Su Y, He L, Liu Z, Zhang J, Li Y, Zhang X, Liu Q, Liu Z, Li X, Mei L, Liu Y, Ji T, Wang S.
Zhang G, et al.
Head Neck. 2024 Apr;46(4):905-914. doi: 10.1002/hed.27637. Epub 2024 Jan 12.
Head Neck. 2024.
PMID: 38214480
RESULTS: Of 21 patients with nasolabial fold RMS, 90.48% were alveolar subtype, in which PAX3/7-FOXO1 fusion positive accounted for 87.5%. ...Almost all patients received comprehensive treatment (chemotherapy [100%], radiation therapy [100%], and surge …
RESULTS: Of 21 patients with nasolabial fold RMS, 90.48% were alveolar subtype, in which PAX3/7-FOXO1 fusion positive a …
Item in Clipboard
NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis.
Lai JP, Robbins PF, Raffeld M, Aung PP, Tsokos M, Rosenberg SA, Miettinen MM, Lee CC.
Lai JP, et al.
Mod Pathol. 2012 Jun;25(6):854-8. doi: 10.1038/modpathol.2012.31. Epub 2012 Mar 2.
Mod Pathol. 2012.
PMID: 22388761
Free PMC article.
A promising targeted therapy against NY-ESO-1 (CTAG 1B) using genetically modified T-cells in synovial sarcomas was recently demonstrated in a clinical trial at the NCI. To investigate the role of NY-ESO-1 immunohistochemistry in patient selection and gain better insight i …
A promising targeted therapy against NY-ESO-1 (CTAG 1B) using genetically modified T-cells in synovial sarcomas was recently demonstr …
Item in Clipboard
Cite
Cite